Patents by Inventor Karen Lesley Schofield

Karen Lesley Schofield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8278442
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: October 2, 2012
    Assignee: Prosidion Limited
    Inventors: Jason Bloxham, Stuart Edward Bradley, Tom Banksia Dupree, Peter Timothy Fry, Patrick Eric Hanrahan, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John Stewart
  • Publication number: 20120214808
    Abstract: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: Prosidion Limited
    Inventors: Jason Bloxham, Matthew Colin Thor Fyfe, James Horswill, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Karen Lesley Schofield, Salam Shaaban, Simon Andrew Swain, Philippe Wong-Kai-In
  • Patent number: 8207147
    Abstract: Compounds of Formula (I), R1-A-V—B—R2; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: June 26, 2012
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Lisa Sarah Gardner, John King-Underwood, Martin James Procter, Chrystelle Marie Rasamison, Karen Lesley Schofield, Gerard Hugh Thomas
  • Patent number: 8158622
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 17, 2012
    Assignee: Prosidion Limited
    Inventors: Stuart Edward Bradley, Thomas Martin Krulle, Peter John Murray, Martin James Procter, Robert John Rowley, Colin Peter Sambrook Smith, Gerard Hugh Thomas, Karen Lesley Schofield
  • Publication number: 20120077793
    Abstract: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 29, 2012
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Peter Timothy Fry, Matthew Colin Thor Fyfe, William Gattrell, Revathy Perpetua Jeevaratnam, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John William Stewart, David French Stonehouse, Simon Andrew Swain
  • Publication number: 20120059014
    Abstract: The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 8, 2012
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Tom Banksia Dupree, Peter Timothy Fry, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, Thomas Martin Krulle, Karen Lesley Schofield, Donald Smyth, Thomas Staroske, Alan John William Stewart, David French Stonehouse, Simon Andrew Swain, David Matthew Withall
  • Publication number: 20120040953
    Abstract: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: March 12, 2010
    Publication date: February 16, 2012
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Susan Helen Davis, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, Karen Lesley Schofield, Thomas Staroske, Alan John William Stewart, Simon Andrew Swain, David Matthew Withall
  • Patent number: 8063247
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: November 22, 2011
    Assignee: Prosidion Limited
    Inventors: Jason Bloxham, Stuart Edward Bradley, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth
  • Publication number: 20100286112
    Abstract: The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: September 10, 2008
    Publication date: November 11, 2010
    Inventors: Oscar Barba, Stuart Edward Bradley, Matthew Colin Thor Fyfe, Patrick Eric Hanrahan, Thomas Martin Krulle, Martin James Procter, Christine Reynet McCormack, Karen Lesley Schofield, Donald Smyth, Alan John William Stewart, Simon Andrew Swain, Peter Widdowson
  • Publication number: 20100267780
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.
    Type: Application
    Filed: September 8, 2008
    Publication date: October 21, 2010
    Inventors: Jason Bloxham, Stuart Edward Bradley, Thomas Martin Krulle, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth
  • Publication number: 20100173886
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.
    Type: Application
    Filed: May 22, 2008
    Publication date: July 8, 2010
    Inventors: Jason Bloxham, Stuart Edward Bradley, Tom Banksia Dupree, Peter Timothy Fry, Patrick Eric Hanrahan, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John Stewart
  • Patent number: 7582632
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: September 1, 2009
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Lisa Sarah Gardner, Maseo Nawano, Martin James Procter, Chrystelle Marie Rasamison, Karen Lesley Schofield, Vilasben Kanji Shah, Kosuke Yasuda
  • Publication number: 20080261952
    Abstract: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.
    Type: Application
    Filed: August 16, 2005
    Publication date: October 23, 2008
    Inventors: Jason Bloxham, Matthew Colin Thor Fyfe, James Horswill, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Karen Lesley Schofield, Salam Shaaban, Andrew Simon Swain, Phillppe Wong-Kai-In
  • Patent number: 7214681
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: May 8, 2007
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Lisa Sarah Gardner, Maseo Nawano, Martin James Procter, Chrystelle Marie Rasamison, Karen Lesley Schofield, Vilasben Kanji Shah, Kosuke Yasuda
  • Patent number: 7115745
    Abstract: The present invention is directed to a new class of 6-benzyl urea/thiourea-quinolin-2-one derivatives and 2-oxo-6-benzylurea/thiourea-chromene derivatives. These compound are androgen antagonists and are useful in the treatment of alopecia, acne and other conditions associated with inappropriate activation of the androgen receptor.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: October 3, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Martin James Procter, Matthew Colin Thor Fyfe, Vilasben Kanji Shah, Geoffrey Martyn Williams, Karen Lesley Schofield
  • Patent number: 7098340
    Abstract: The present invention is directed to a new class of 6-benzylsulfonamido-quinoline/chromene derivatives, to their use as androgen antagonists, and to formulations containing these androgen antagonists.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: August 29, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Martin James Procter, Matthew Colin Thor Fyfe, Vilasben Kanji Shah, Geoffrey Martyn Williams, Karen Lesley Schofield
  • Patent number: 7074933
    Abstract: The invention is directed to a new class of quinolin-zene and z-exc chromen compounds that have been derivatized at the 6-position with a urea or this urea moet, and to then use as androgen antagonists.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: July 11, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Martin James Procter, Matthew Colin Thor Fyfe, Vilasben Kanji Shah, Geoffrey Martyn Williams, Karen Lesley Schofield
  • Patent number: 7064207
    Abstract: The present invention is directed to a new class of 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives to their use as androgen antagonists, and to relieve conditions associated with inappropriate activation of the androgen receptor.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: June 20, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Matthew Colin Thor Fyfe, Martin James Procter, Karen Lesley Schofield, Vilasben Kanji Shah, Geoffrey Martyn Williams
  • Patent number: 7057048
    Abstract: The present invention is directed to a new class of 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives to their use as androgen antagonists, and to relieve conditions associated with inappropriate activation of the androgen receptor.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: June 6, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Matthew Colin Thor Fyfe, Martin James Procter, Karen Lesley Schofield, Vilasben Kanji Shah, Geoffrey Martyn Williams
  • Patent number: 7009052
    Abstract: The present invention is directed to a new class of 6-sulfonamide quinoline and chromene derivative and to their use as androgen antagonists.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: March 7, 2006
    Assignee: Warner Lambert Company LLC
    Inventors: Daniel Y. Du, Matthew Colin Thor Fyfe, Martin James Procter, Karen Lesley Schofield, Vilasben Kanji Shah, Geoffrey Martyn Williams